This paper is only available as a PDF. To read, Please Download here.
Neurogenic bowel (NB) affects up to 60% of people with spinal cord injury (SCI) and
is characterized by slow colonic transit, constipation, and chronic abdominal pain.
NB rarely resolves and tends to worsen over time, making it a long-term physical and
psychological challenge for people with SCI. The knowledge gap surrounding the underlying
mechanisms of NB after SCI means that interventions are symptom-focused with only
modest gains reported. Identifying the mechanism(s) that initiate and maintain NB
after SCI is critically important to the development of evidence-based, novel therapeutic
options for bowel dysfunction and pain after SCI. Using a translational spinal contusion
mouse model that recapitulates the clinical NB symptoms after SCI, we can begin to
tease apart the mechanisms underlying NB. Preliminary analyses using this model indicate
a rapid and persistent increased expression of inflammatory mediators, expansion of
lymphatic nodules, and disruption of the sterile intestinal mucus bilayer. Without
the protective mucus barrier, microbes are observed translocating into the intestinal
wall as early as 24 hours. These bacteria are known to initiate local host gene expression
changes and may contribute to long term negative health outcomes. Follow-up analyses
identified a corresponding upregulation in mRNA transcripts related to bacterial stimulation
and defense responses in primary spinal afferents as well as hyperresponsiveness of
primary vagal afferents to autologous stool samples. The potentially maladaptive colonic
inflammation and host-microbiome interactions provide a biological substrate for NB
after SCI with the potential for novel therapeutic interventions targeting these biological
processes to prevent or treat NB.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.